Liquidia Corporation (LQDA)
Will LQDA's Differentiated PAH Approach Drive Growth?
LQDA's Yutrepia is driving rapid growth, but intensifying PAH competition could test its ability to sustain momentum.
Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion?
Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.
LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now?
Liquidia's Yutrepia is fueling rapid growth, but patent litigation, competition and heavy product dependence weigh on its outlook.
LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth
Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.
LQDA Q2 Earnings Call Highlights YUTREPIA and $1B 2027 Revenue Path
Liquidia targets more than $1 billion in 2027 net revenues as YUTREPIA gains share and funds a broader inhaled-treprostinil pipeline.
Liquidia: YUTREPIA's Launch Opens Upside If Growth Remains And Margins Follow
YUTREPIA's commercial launch continues to scale, with Q2 product sales of $170.4 million, up 31% sequentially. Q2 largely resolved the margin concern: product gross margin remained about 93.7% despite fully costed inventory, while operating margin reached roughly 49.8%. The key debate has shifted from profitability to growth. Liquidia now needs about $210 million of quarterly revenue in Q3 and Q4 to reach the current $725 million FY2026 consensus.
Liquidia Corporation (LQDA) Q2 2026 Earnings Call Transcript
Liquidia Corporation (LQDA) Q2 2026 Earnings Call Transcript
Liquidia Q2 Earnings Call Highlights
Liquidia NASDAQ: LQDA reported second-quarter 2026 results marked by continued growth for its inhaled treprostinil product YUTREPIA, increased profitability and expanding investment in its clinical pipeline.
Liquidia Corporation (LQDA) Q2 Earnings and Revenues Beat Estimates
Liquidia Corporation (LQDA) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.7 per share. This compares to a loss of $0.49 per share a year ago.
3 Low-Beta Stocks to Minimize Portfolio Risk: LQDA, PBF & FET
Liquidia, PBF Energy and Forum Energy Technologies pair low beta with positive momentum and growth drivers amid market volatility.
Should You Invest in Liquidia Corporation Stock Ahead of Q2 Earnings?
LQDA heads into its Q2 earnings with Yutrepia driving growth, rising profitability and a self-funded pipeline as investors watch quarterly performance.
3 Low-Beta Stocks to Minimize Portfolio Risk: LQDA, ET & PBF
Liquidia, Energy Transfer and PBF Energy offer low-beta exposure as oil-driven volatility rises, backed by growth, stable fees and refining demand.
